Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD).

Saved in:

Bibliographic Details
Title:	Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD).
Authors:	Hong, Jennifer¹ HongJe@mlhs.org, Johnson, William T.² JohnsoW3@mskcc.org, Kartan, Saritha³ Saritha.Kartan@jefferson.edu, Gonsalves, Anitha S.⁴ anvids@gmail.com, Fenkel, Jonathan M.⁵ Jonathan.Fenkel@jefferson.edu, Gong, Jerald Z.⁶ Jerald.Gong@jefferson.edu, Porcu, Pierluigi³ Pierluigi.Porcu@jefferson.edu
Source:	Current Oncology. Dec2021, Vol. 28 Issue 6, p5067-5072. 6p.
Database:	Academic Search Ultimate

Description
ISSN:	11980052
DOI:	10.3390/curroncol28060426